Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells.

P. Harding,P. Harding,L. Balasubramanian,J. Swegan,A. Stevens,W. Glass

DOI: https://doi.org/10.1038/SJ.KI.5000323

IF: 19.6

2006-05-01

Kidney International

Abstract:

What problem does this paper attempt to address?

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Ning Li,Li-Jun Wang,Bo Jiang,Shu-Ju Guo,Xiang-Qian Li,Xue-Chun Chen,Jiao Luo,Chao Li,Yi Wang,Da-Yong Shi

DOI: https://doi.org/10.1016/j.bmcl.2018.05.022

IF: 2.94

2018-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A series of novel pyrimidinedione derivatives were designed and evaluated for in vitro dipeptidyl peptidase-4 (DPP-4) inhibitory activity and in vivo anti-hyperglycemic efficacy. Among them, the representative compounds 11, 15 and 16 showed excellent inhibitory activity of DPP-4 with IC50 values of 64.47 nM, 188.7 nM and 65.36 nM, respectively. Further studies revealed that compound 11 was potent in vivo hypoglycemic effect. The structure-activity relationships of these pyrimidinedione derivatives had been discussed, which would be useful for developing novel DPP-4 inhibitors as treating type 2 diabetes.
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Neng Jiang,Lin Jing,Qing Li,Sibiao Su,Qimeng Yang,Feng Zhou,Xinyu Chen,Jing Han,Chunli Tang,Weizhong Tang

DOI: https://doi.org/10.1016/j.ejmech.2020.113118

IF: 7.088

2021-02-01

European Journal of Medicinal Chemistry

Abstract:<p>Dual activation of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) has the potential to lead to an effective therapy for the treatment of diabetes and obesity. Here, we report the discovery of a series of peptides with dual activity on GLP-1R and GCGR that were discovered by rational design. Structural elements of oxyntomodulin (OXM), glucagon or exendin-4 were engineered into the selective GLP-1R agonist <em>Xenopus</em> GLP-1 (xGLP-1) on the basis of sequence analysis, resulting in hybrid peptides with potent dual activity at GLP-1R and GCGR. Further modifications with fatty acid resulted in a novel metabolically stable peptide (xGLP/GCG-15) with enhanced and balanced GLP-1R and GCGR activations. This lead peptide was further explored pharmacologically in both <em>db/db</em> and diet-induced obesity (DIO) rodent models. Chronic administration of xGLP/GCG-15 significantly induced hypoglycemic effects and body weight loss, improved glucose tolerance, and normalized lipid metabolism, adiposity, and liver steatosis in relevant rodent models. These preclinical studies suggest that xGLP/GCG-15 has potential for development as a novel anti-obesity and/or anti-diabetic candidate. Considering the equal effects of xGLP/GCG-15 and the clinical candidate MEDI0382 on reverse hepatic steatosis, it may also be explored as a new therapy for nonalcoholic steatohepatitis (NASH) in the future.</p>

chemistry, medicinal
WITHDRAWN: Design and Evaluation of GLP-1 Receptor G-protein Biased Agonist with Prolonged Efficacy on Diabetes

Peng Zhou,Xiaodan Jiang,Xuemin Li

DOI: https://doi.org/10.1016/j.lfs.2021.119844

IF: 6.78

2021-01-01

Life Sciences

Abstract:AIM:Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as potent drug development target for treating diabetes and obesity. Here, we designed and evaluated novel long-acting GLP-1R G protein biased agonist with potent clinical application.MAIN METHODS:GLP-1R G-protein biased sequences were screened via a high-throughput autocrine-based strategy and then fused to Exendin (9-39). These fusion peptides were further performed with site-specific modification. Surface plasmon resonance (SPR) measurements, GLP-1R activation potencies and plasma stability tests were applied to screen optimal candidate. Acute and chronic hypoglycemic and insulinotropic activities of selected agent were evaluated in diabetic and obese rodent animals.MAIN FINDINGS:AX09 exert highest binding affinities for GLP-1R extracellular domain (GLP-1R ECD). Further in vitro plasma stability and GLP-1R activation assays demonstrated better potency of AX18. Acute pharmacodynamic evaluation of AX18 demonstrated the promising insulinotropic and hypoglycemic activities which were exhibited in a dose-dependent manner. Prolonged hypoglycemic efficacies of AX18 were also observed in both hypoglycemic duration test and multiple oral glucose tolerance tests (OGTTs) in the diabetic mice. Further pharmacokinetic test in cynomolgus monkeys exhibited that the half-life of AX18 was more than 6 days. Once weekly treatment of AX18 in diabetic mice for 8-week achieved significantly improved %HbA1C, insulin resistance, glucose tolerance, β-cells and diabetic retinal injury. Chronic treatment of AX18 in diet-induced obese (DIO) mice also exhibited beneficial efficacies on %HbA1C, inflammation-related factors lowering, and weight gains.CONCLUSION:AX18, as a novel GLP-1R G protein biased agonist, exhibited potency for treating diabetes mellitus and its complications.
Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists

Lili Chen,Ying Yun,Shimeng Guo,Xiaoyan Wang,Muya Xiong,Tingting Zhao,Tifei Xu,Jianhua Shen,Xin Xie,Kai Wang

DOI: https://doi.org/10.1021/acs.jmedchem.3c00320

IF: 8.039

2023-06-08

Journal of Medicinal Chemistry

Abstract:Danuglipron is the most representative small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) and has received considerable attention due to positive results in the treatment of type 2 diabetes mellitus (T2DM) and obesity in clinical trials. However, hERG inhibition, lower activity than endogenous GLP-1, and a short action time represent limitations in terms of feasible application. In this study, we report a new class of 5,6-dihydro-1,2,4-triazine derivatives that serve to...

chemistry, medicinal
Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Zheng Li,Chunxia Liu,Jianyong Yang,Jiaqi Zhou,Zhiwen Ye,Dazhi Feng,Na Yue,Jiayi Tong,Wenlong Huang,Hai Qian

DOI: https://doi.org/10.1016/j.ejmech.2019.06.087

2019-10-01

Abstract:Based on an old phenoxyacetic acid scaffold, CPU014 (compound 14) has been identified as a superior agonist by comprehensive exploration of structure-activity relationship. In vitro toxicity study suggested that CPU014 has lower risk of hepatotoxicity than TAK-875. During acute toxicity study (5-500 mg/kg), a favorable therapeutic window of CPU014 was observed by evaluation of plasma profiles and liver slices. Moreover, CPU014 promotes insulin secretion in a glucose-dependent manner, while no GLP-1 secretion has been enhanced. Other than good pharmacokinetic properties, CPU014 significantly improved glucose tolerance both in normal and diabetic models without the risk of hypoglycemia. These subversive findings provided a safer candidate CPU014, which is currently in preclinical study to assess its potential for the treatment of diabetes.
Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Zongtao Zhou,Zongyu Cai,Congzi Zhang,Benhui Yang,Lianru Chen,Yepu He,Luyong Zhang,Zheng Li

DOI: https://doi.org/10.1016/j.bmc.2022.116615

2022-02-01

Abstract:The free fatty acid receptor 1 (FFA1/GPR40) and peroxisome proliferator-activated receptor δ (PPARδ) have been widely considered as promising targets for type 2 diabetes mellitus (T2DM) due to their respective roles in promoting insulin secretion and improving insulin sensitivity. Hence, the dual FFA1/PPARδ agonists may exert synergistic effects by simultaneously activating FFA1 and PPARδ. The present study performed systematic exploration around previously reported FFA1 agonist 2-(2-fluoro-4-((2'-methyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenoxy)acetic acid (lead compound), leading to the identification of a novel dual FFA1/PPARδ agonist 2-(2-fluoro-4-((3-(6-methoxynaphthalen-2-yl)benzyl)oxy)phenoxy)acetic acid (the optimal compound), which displayed high selectivity over PPARα and PPARγ. In addition, the docking study provided us with detailed binding modes of the optimal compound in FFA1 and PPARδ. Furthermore, the optimal compound exhibited greater glucose-lowering effects than lead compound, which might attribute to its synergistic effects by simultaneously modulating insulin secretion and resistance. Moreover, the optimal compound has an acceptable safety profile in the acute toxicity study at a high dose of 500 mg/kg Therefore, our results provided a novel dual FFA1/PPARδ agonist with excellent glucose-lowering effects in vivo.

biochemistry & molecular biology,chemistry, medicinal, organic
Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

Zhijun Li,jeffrey A. Campbell,Phu Do,Zhiyu Li,Faisal Malik

DOI: https://doi.org/10.1124/jpet.478.921550

2024-05-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:ID 92155 Poster Board 478 The Glucagon-like peptide 1 receptor (GLP-1R) belongs to the Class B G-protein coupled receptors (GPCRs) and is a well-established target for treating type 2 diabetes. Recent clinical-trial data suggest that GLP-1R agonistic drugs not only significantly reduce body weight in individuals with obesity, but may also offer protection against serious heart disease and drug/alcohol addiction related issues. Consequently, GLP-1R has become one of the most intriguing and extensively studied Class B GPCRs. Although GLP-1R agonist-based therapies, including various GLP-1 analog drugs, are highly successful and available in the market, most are peptidic in nature and require intravenous ( iv ) mode of administration. Thus, it remains a challenge to develop nonpeptidic agonist drugs targeting GLP-1R. A promising approach, involves the development of small molecule positive allosteric modulators (PAMs) of GLP-1R, which have a greater potential for more convenient oral ( po ) administration. Building upon our prior work that identified two 2-aminothiophene-based small-molecule PAMs of GLP-1R, we conducted a series of structural SAR optimizations, as well as in vitro and in vivo studies. This effort led to the identification of 2-aminothiophene derivative, I-187 (MW 299), which exhibited an approximately 2-fold increase in insulin secretion at 5 μM when combined with the GLP-1 peptide at 10 nM. I n vivo studies using CD1 mice revealed a 50% reduction in glucose levels after 60 minutes at a dose of 10 mg/kg b.w. More notably, co-treatment with sitagliptin, an inhibitor of the GLP-1 degrading enzyme dipeptidyl peptidase IV, demonstrated that I-187 synergistically lowered blood glucose levels by approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. These promising results, coupled with the favorable drug-like properties of the compound, suggest that I-187 is a compelling lead compound for future drug development. Furthermore, this approach can potentially be applied to the development of allosteric modulation of other GPCRs. This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R15GM140406.

pharmacology & pharmacy
753-P: RGT-075, an Orally Efficacious Small Molecule GLP-1R Full Agonist in Cynomolgus Monkey Models

Feng Liu,Xianqiang Sun,Wei Huang,Wei Guo,Jing Lin,Wenge Zhong

DOI: https://doi.org/10.2337/db22-753-p

IF: 7.7

2022-01-01

Diabetes

Abstract:Activation of Glucagon-like peptide-1 receptor (GLP-1R) by peptides has been proven clinically to be a very effective treatment approach for type 2 diabetes (T2D) and obesity. Here we describe a small molecule GLP-1R full agonist RGT-075 identified through Computer Accelerated Rational Design (CARD) (Ma et al., Cell Research 2020) with nM potency in G-protein coupled cAMP signaling. RGT-075 displayed much reduced activity in receptor-mediated β-arrestin recruitment and subsequent internalization. It was shown to be selective against other class B G protein-coupled receptors (GPCRs) and was only active for human and monkey GLP-1R. It demonstrated favorable oral bioavailability and pharmacodynamic profile for once-daily oral dosing in monkeys. In food-induced glucose intolerant and prediabetic cynomolgus monkeys, oral administration of RGT-075 improved glucose tolerance to a level comparable to injectable liraglutide. In food-induced type 2 diabetic monkeys, once-daily oral administration of RGT-075 reduced food intake and fasting plasma glucose levels. Together, these data support the development and advancement of RGT-075 into the clinic as a potential therapeutic for T2D and obesity. Disclosure F.Liu: Employee; Regor Pharmaceuticals Inc. X.Sun: Employee; AutoDrug Biotech Co. Ltd., Qilu Regor Therapeutics Inc. W.Huang: None. W.Guo: None. J.Lin: None. W.Zhong: None.
Design of a Novel Long-Acting Dual GLP-1/GIP Receptor Agonist

Yuanzhen Dong,Jinhua Zhang,Hongjiang Xu,Hengqiao Shen,Qin Lu,Jun Feng,Zhengyan Cai

DOI: https://doi.org/10.1016/j.bmc.2024.117630

IF: 3.461

2024-02-04

Bioorganic & Medicinal Chemistry

Abstract:Tirzepatide, the first approved dual GLP-1/GIP receptor agonist (RA), has achieved better clinical outcomes than other GLP-1RAs. However, it is an imbalanced dual GIP/GLP-1 RA, and it remains unclear whether the degree of imbalance is optimal. Here, we present a novel long-acting dual GLP-1/GIP RA that exhibits better activity than tirzepatide toward GLP-1R. A candidate conjugate, D314, identified via peptide design, synthesis, conjugation, and experimentation, was evaluated using chronic studies in db/db and diet induced obese (DIO) mice. D314 achieved favorable blood glucose and body weight-lowering effects, equal to those of tirzepatide. Its half-life in dogs (T 1/2 : 78.3 ± 14.01 h) reveals its suitability for once-weekly administration in humans. This preclinical study suggests the potential role of D314 as an effective agent for treating T2DM and obesity.

biochemistry & molecular biology,chemistry, medicinal, organic
Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists

Shizhen Zhao,Le Wang,Jie Wang,Chenwei Wang,Shaowei Zheng,Yajie Fu,Yunfu Li,Wei-Dong Chen,Ruifang Hou,Dongbin Yang,Yan-Dong Wang

DOI: https://doi.org/10.1039/d1ra08867j

IF: 4.036

2022-01-01

RSC Advances

Abstract:The most potent compound 18k exhibited excellent hTGR5 agonist activity, which was superior to those of the reference drugs INT-777. In addition, compound 18k could significantly reduce blood glucose levels and stimulate GLP-1 secretion in C57 BL/6 mice.

chemistry, multidisciplinary
Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Fenghui Zhao,Qingtong Zhou,Zhaotong Cong,Kaini Hang,Xinyu Zou,Chao Zhang,Yan Chen,Antao Dai,Anyi Liang,Qianqian Ming,Mu Wang,Linan Chen,Peiyu Xu,Rulue Chang,Wenbo Feng,Tian Xia,Yan Zhang,Beili Wu,Dehua Yang,Lihua Zhao,H. Eric Xu,Ming-Wei Wang

DOI: https://doi.org/10.1101/2021.07.29.454286

2021-01-01

bioRxiv

Abstract:Glucose homeostasis, regulated by glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) is critical to human health. Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dualagonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their superior efficacies over monoagonist such as semaglutide, we determined cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the atomic level. Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy. Our findings provide valuable insights into the structural basis of functional versatility and therapeutic supremacy of tirzepatide and peptide 20. ### Competing Interest Statement The authors have declared no competing interest.
Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Zhaotong Cong,Li-Nan Chen,Honglei Ma,Qingtong Zhou,Xinyu Zou,Chenyu Ye,Antao Dai,Qing Liu,Wei Huang,Xianqiang Sun,Xi Wang,Peiyu Xu,Lihua Zhao,Tian Xia,Wenge Zhong,Dehua Yang,H. Eric Xu,Yan Zhang,Ming-Wei Wang

DOI: https://doi.org/10.1038/s41467-021-24058-z

2021-01-01

Abstract:The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator); (ii) compound 2 and GLP-1; and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with heterotrimeric G s . The structures reveal that compound 2 is covalently bonded to C347 at the cytoplasmic end of TM6 and triggers its outward movement in cooperation with the ECD whose N terminus penetrates into the GLP-1 binding site. This allows compound 2 to execute positive allosteric modulation through enhancement of both agonist binding and G protein coupling. Our findings offer insights into the structural basis of ago-allosterism at GLP-1R and may aid the design of better therapeutics.
Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

Shizhen Zhao,Xinping Li,Le Wang,Wenjing Peng,Wenling Ye,Weiguo Li,Yan-Dong Wang,Wei-Dong Chen

DOI: https://doi.org/10.1016/j.bmc.2020.115972

2021-02-01

Abstract:<p>TGR5 is emerging as an important and promising target for the treatment of diabetes, obesity and other metabolic syndromes. A series of novel 1-benzyl-1<em>H</em>-imidazole-5-carboxamide derivatives was designed, synthesized and evaluated <em>in vitro</em> and <em>in vivo</em>. The most potent compounds 19d and 19e exhibited excellent agonistic activities against hTGR5, which was superior to those of the reference drugs INT-777 and LCA. In addition, compounds 19d and 19e exhibited good selectivity against FXR and presented significant glucose-lowering effects in vivo. Compound 19d could stimulate GLP-1 secretion by activating of TGR5.</p>

biochemistry & molecular biology,chemistry, medicinal, organic
Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Yang Liu,Meimei Si,Li Tang,Shihao Shangguan,Haoshu Wu,Jia Li,Peng Wu,Xiaodong Ma,Tao Liu,Yongzhou Hu

DOI: https://doi.org/10.1016/j.bmc.2013.07.034

IF: 3.461

2013-01-01

Bioorganic & Medicinal Chemistry

Abstract:A series of novel benzyl-substituted (S)-phenylalanine derivatives were synthesized and evaluated for their dipeptidyl peptidase 4 (DPP-4) inhibitory activity and selectivity. It was found that most synthesized target compounds were potent DPP-4 inhibitors with IC50 values in 3.79-25.52 nM, which were significantly superior to that of the marketed drug sitagliptin. Furthermore, the 4-fluorobenzyl substituted phenylalanine derivative 6g not only displayed the potent DPP-4 inhibition with an IC50 value of 3.79 nM, but also showed better selectivity against DPP-4 over other related enzymes including DPP-7, DPP-8, and DPP-9. In an oral glucose tolerance test (OGTT) in normal Sprague Dawley rats, compound 6g reduced blood glucose excursion in a dose-dependent manner.
Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1h-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes.

Yusheng Xiong,Jian Guo,Mari R. Candelore,Rui Liang,Corey Miller,Qing Dallas-Yang,Guoqiang Jiang,Peggy E. McCann,Sajjad A. Qureshi,Xinchun Tong,Shiyao Sherrie Xu,Jackie Shang,Stella H. Vincent,Laurie M. Tota,Michael J. Wright,Xiaodong Yang,Bei B. Zhang,James R. Tata,Emma R. Parmee

DOI: https://doi.org/10.1021/jm300579z

IF: 8.039

2012-01-01

Journal of Medicinal Chemistry

Abstract:A potent, selective glucagon receptor antagonist 9m, N-[(4-{(1S)-1-[3-(3,5-dichlorophenyl) -5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)-carbonyl]-beta-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.
Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity

Jiandong Yuan,Wenlang Liu,Xiaohui Jiang,Yangqing Huang,Leilei Zong,Haifeng Ding,Xinyi Shen,Yujia Sun,Xiangyang Feng,Xionghao Li,Yunsong Song,Jianing Gu,Yuhuai Wang,Hao Liu,Zheng Zheng

DOI: https://doi.org/10.1038/s41598-024-66998-8

IF: 4.6

2024-07-21

Scientific Reports

Abstract:The dual activation of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has emerged as a promising therapeutic strategy for managing type 2 diabetes and obesity. Tirzepatide, a dual agonist peptide, has exhibited superior clinical efficacy in glycemic and weight control compared to selective GLP-1R agonists. Nevertheless, the structural basis of Tirzepatide's extended half-life, attributed to an acylation side chain on the parent peptide, raises questions regarding its partial agonistic activity. Employing molecular dynamics simulations, we explored the dynamic processes of peptide-receptor interactions. We uncovered a crucial salt bridge between parent peptide and GLP-1R/GIPR at K20, a feature not discernible in cryo-electron microscopy structures. Building upon these insights, we developed an optimization strategy based on the parent peptide which involved repositioning the acylation side chain. The results of both in vitro and in vivo experiments demonstrated that the optimized peptide has twofold to threefold increase in agonistic activity compared to Tirzepatide while maintaining its extended half-life in plasma. This led to the design of BGM0504, which proved to be more effective than its predecessor, Tirzepatide, in both laboratory and animal studies.

multidisciplinary sciences
Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals

Jie Cui,Anquan Shang,Weiwei Wang,Wei Chen

DOI: https://doi.org/10.1016/j.lfs.2020.118339

IF: 6.78

2020-11-01

Life Sciences

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>To design and screen a potent GLP-1/GIP/Gcg receptors triagonist with therapeutic potential in rodent animals with diabetes and obesity.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main methods</h3><p>First, we obtained a 12-mer dual GIP/Gcg receptor agonist from a large combinatorial peptide library <em>via</em> high-throughput screening technique and then fused to the Exendin (9–39) to generate a potent GLP-1/GIP/Gcg triagonist. Further site fatty chain modification was performed to improve the druggability <em>via</em> enhancing <em>in vivo</em> stability and cyclic half-life. <em>In vitro</em> signaling and functional assays in cell lines expressing each receptor and <em>in vivo</em> efficacy evaluation in rodent model animals with hyperglycemia and obesity were all carefully performed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Key findings</h3><p>We screened and obtained a potent GLP-1/GIP/Gcg triagonist, termed XFL0, which promotes <em>in vitro</em> GLP-1, GIP, Gcg receptor activation comparable to native GLP-1, GIP and glucagon, respectively. Site-specific fatty acid modification significantly enhanced plasma stability of XFL0 and exhibited no obvious impact on receptor activation. The selected XFL0 conjugates termed XFL6, showed glucose-dependent insulin secretion and improved glucose tolerance by acting on all GLP-1, GIP and Gcg receptors in gene-deficient mice of which the effects were all significantly greater than any single receptor agonist. After chronic treatment in rodent animals with diabetes and obesity, XFL6 potently decreased body weight and food intake, ameliorated the hyperglycemia and hemoglobin A1c levels as well as the lipid metabolism and diabetic nephropathy related disorders.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>XFL6, as a novel GLP-1/GIP/Gcg receptor triagonist, held potential to deliver outstanding improvement in correcting hyperglycemia, obesity and diabetic nephropathy.</p>

pharmacology & pharmacy,medicine, research & experimental
Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine.

Hsin-Chieh Tang,Calvin Yu-Chian Chen

DOI: https://doi.org/10.1155/2014/385120

2014-01-01

Abstract:Glucagon-like peptide-1 (GLP-1) is a promising target for diabetes mellitus (DM) therapy and reduces the occurrence of diabetes due to obesity. However, GLP-1 will be hydrolyzed soon by the enzyme dipeptidyl peptidase-4 (DPP-4). We tried to design small molecular drugs for GLP-1 receptor agonist from the world's largest traditional Chinese medicine (TCM) Database@Taiwan. According to docking results of virtual screening, we selected 2 TCM compounds, wenyujinoside and 28-deglucosylchikusetsusaponin IV, for further molecular dynamics (MD) simulation. GLP-1 was assigned as the control compound. Based on the results of root mean square deviation (RMSD), solvent accessible surface (SAS), mean square deviation (MSD), Gyrate, total energy, root mean square fluctuation (RMSF), matrices of smallest distance of residues, database of secondary structure assignment (DSSP), cluster analysis, and distance of H-bond, we concluded that all the 3 compounds could bind and activate GLP-1 receptor by computational simulation. Wenyujinoside and 28-deglucosylchikusetsusaponin IV were the TCM compounds that could be GLP-1 receptor agonists.
Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives As Potent and Orally Efficacious TGR5 Agonists.

Hongliang Duan,Mengmeng Ning,Xiaoyan Chen,Qingan Zou,Liming Zhang,Ying Feng,Lina Zhang,Ying Leng,Jianhua Shen

DOI: https://doi.org/10.1021/jm301071h

IF: 8.039

2012-01-01

Journal of Medicinal Chemistry

Abstract:4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)0-120 min following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.
Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus

Xu Li,Xinmeng Zhang,Xueyuan Xie,Taimin Dong,Chengxu Lv,Ranran Guan,Wenyue Zhang,Guoxia Ji,Fanghui Chen,Shiben Wang,Xuekun Wang

DOI: https://doi.org/10.3390/ijms252111476

IF: 5.6

2024-10-26

International Journal of Molecular Sciences

Abstract:Diabetes mellitus (DM) is a common metabolic disease that poses a severe threat to human health. Despite a range of therapeutic approaches, there remains a lack of effective and safe therapies with the existing drugs. Therefore, there is an urgent need to develop novel, effective, and safe therapeutic strategies for DM. Free fatty acid receptor 4 (FFAR4), also known as GPR120, is a member of the G protein-coupled receptor family, which has received considerable attention as an attractive new therapeutic target for treating DM. In the present study, based on the structure of TUG-891, which has excellent activity and selectivity, a series of novel FFAR4 agonists was designed by replacing the phenylpropanoic acid β position carbon atom with an oxygen atom, while replacing the linking oxymethylene with an amide-linking group. The target compounds were evaluated for FFAR4 agonistic activity, and the preferred compounds were evaluated for selectivity, oral glucose tolerance in normal ICR mice, antidiabetic activity in diet-induced obese (DIO) mice, pharmacokinetic properties in ICR mice and molecular modeling studies. The results showed that compound 10f possessed excellent FFAR4 agonistic activity and selectivity, significantly improved glucose tolerance in normal ICR mice, lowered blood glucose and promoted insulin secretion in a dose-dependent manner in DIO mice, and showed favorable pharmacokinetic properties. These results indicate that compound 10f may be a promising compound that deserves further structure–activity relationship and pharmacological studies for the development of antidiabetic drugs.

biochemistry & molecular biology,chemistry, multidisciplinary

Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells.

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

WITHDRAWN: Design and Evaluation of GLP-1 Receptor G-protein Biased Agonist with Prolonged Efficacy on Diabetes

Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

753-P: RGT-075, an Orally Efficacious Small Molecule GLP-1R Full Agonist in Cynomolgus Monkey Models

Design of a Novel Long-Acting Dual GLP-1/GIP Receptor Agonist

Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1h-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes.

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity

Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine.

Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives As Potent and Orally Efficacious TGR5 Agonists.

Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus